6533b834fe1ef96bd129d60a
RESEARCH PRODUCT
Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis.
Adrián H. TeruelPablo GaviñaPablo GaviñaFélix SancenónMargarita ParraMargarita ParraAna M. CosteroAna M. CosteroVirginia MerinoVirginia MerinoDaniel FerriDaniel FerriRamón Martínez-máñezsubject
DrugBudesonideMalemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineDrug Delivery SystemsIn vivomedicineAnimalsColitisBudesonideTnbs colitismedia_commonChemistryMesoporous silica021001 nanoscience & nanotechnologymedicine.diseaseColitisSilicon DioxideControlled releasedigestive system diseasesRatsTargeted drug deliveryTrinitrobenzenesulfonic Acid0210 nano-technologyAzo Compoundsmedicine.drugdescription
Abstract A colon targeted drug delivery system for inflammatory bowel diseases (IBD), consisting in budesonide loaded mesoporous silica microparticles functionalized with a selective azo-molecular gate (M-Bud), has been evaluated for in vivo efficacy. Experimental colitis in male Wistar rats was induced by rectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS). M-Bud was orally administered to the rats as a suspension in water. Colon/body weight ratio, clinical activity score, and histological evaluation were used as inflammatory indices to measure the performance of the microparticles. The formulation was compared with a suspension prepared from the commercial drug Entocord®. Statistical analyses of all scores indicate that the controlled release of budesonide in colon from M-Bud showed efficacy similar to that of Entocord in the healing of induced colitis in rats.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-04-01 | International journal of pharmaceutics |